Grace Therapeutics (NASDAQ:GRCE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Grace Therapeutics (NASDAQ:GRCE) to a hold rating in a research report report published on Saturday morning.

Separately, TD Cowen initiated coverage on shares of Grace Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $12.00 price target for the company. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Grace Therapeutics currently has an average rating of “Buy” and a consensus target price of $12.00.

Grace Therapeutics Stock Performance

Shares of Grace Therapeutics stock opened at $3.25 on Friday. The company’s 50-day moving average price is $3.12 and its 200-day moving average price is $2.83. Grace Therapeutics has a 12-month low of $1.75 and a 12-month high of $4.97. The company has a market cap of $44.94 million, a price-to-earnings ratio of -3.78 and a beta of 0.72.

Grace Therapeutics (NASDAQ:GRCE) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. On average, sell-side analysts predict that Grace Therapeutics will post -1.06 earnings per share for the current year.

Hedge Funds Weigh In On Grace Therapeutics

Large investors have recently modified their holdings of the company. Millington Financial Advisors LLC purchased a new stake in Grace Therapeutics in the second quarter worth approximately $59,000. Palumbo Wealth Management LLC bought a new stake in shares of Grace Therapeutics in the 2nd quarter worth approximately $144,000. Stonepine Capital Management LLC bought a new stake in shares of Grace Therapeutics in the 1st quarter worth approximately $666,000. ADAR1 Capital Management LLC purchased a new stake in shares of Grace Therapeutics in the 1st quarter valued at $783,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Grace Therapeutics during the 1st quarter valued at $2,686,000. 6.08% of the stock is owned by hedge funds and other institutional investors.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.